A multicenter phase II trial of ramucirumab plus irinotecan in patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S-1 therapy: RAMIEL trial (OGSG1901). Median PFS and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results